Tag Archives: NICE guidance

Nice Guidance: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Psoriasisplaque
Image: Google Images

Adalimumab, Etanercept & Ustekinumab are recommended as an option for treating plaque psoriasis in children and young people aged 4 years or older, only if the disease:

  • is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
  • has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.

     

    Link to guidance here

NICE guidance: End of life care for infants, children and young people with life-limiting conditions: planning and management

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.

NICE Guidance NG61, published 7th December, 2016